Intuitive Surgical, Inc.

Intuitive Surgical is the dominant robotic-surgery company behind the da Vinci system — a name that traded at premium multiples for a decade on structural procedure growth, and whose stock is now cracking as domestic da Vinci growth slows to a four-year low.

• Q2 was a double beat but the market punished it: revenue of $2.89B (+19% YoY) and EPS $2.80 (+28%) beat consensus, but shares fell 10-13% after-hours on domestic procedure growth slowing to just 12% — the number anchoring the premium multiple.
• Multiple compression is real: at 50x TTM P/E on a business showing decelerating unit growth, the market is repricing toward 30x — even the FY27 forward multiple of ~29x on consensus $12.04 EPS looks fair, not cheap.
• China competitive risk is finally showing up: domestic slowdown plus Chinese surgical-robot competition (Edge Medical, Distal Zenith) is what the bear case has called for years — this doesn't reverse in one quarter.
• Da Vinci 5 is the offset the bulls point to: adoption of the next-gen system is a real growth vector, and the -40% YTD selloff crosses the point where six-plus-year-cheapest frames attract dip-buyers.

Path forward is October 20 Q3 — the number that matters is domestic da Vinci procedure growth reaccelerating above 13%. What restarts the move: a da Vinci 5 US placement acceleration; what invalidates: procedure growth ticking below 10% or a Chinese competitor landing a major US hospital-system contract.